BE1003123A3 - Compositions pharmaceutiques. - Google Patents

Compositions pharmaceutiques. Download PDF

Info

Publication number
BE1003123A3
BE1003123A3 BE9000197A BE9000197A BE1003123A3 BE 1003123 A3 BE1003123 A3 BE 1003123A3 BE 9000197 A BE9000197 A BE 9000197A BE 9000197 A BE9000197 A BE 9000197A BE 1003123 A3 BE1003123 A3 BE 1003123A3
Authority
BE
Belgium
Prior art keywords
matrix
filling
pharmaceutical compositions
ranitidine
glyceride
Prior art date
Application number
BE9000197A
Other languages
English (en)
Inventor
Sham Kumar Chopra
Tarun Tribhovan Makadia
Original Assignee
Glaxo Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Canada filed Critical Glaxo Canada
Application granted granted Critical
Publication of BE1003123A3 publication Critical patent/BE1003123A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention a pour objet une composition pharmaceutique sous forme de gélules de gélatine consistant en un mélange qui contient, à titre d'ingrédient actif, de la ranitidine ou son sel physiologiquement acceptable enrobé d'une enveloppe de gélatine. On prépare le remplissage à base d'une matrice non aqueuse comprenant au moins un glycéride d'acides gras et/ou une huile minérale ou paraffine; de préférence la matrice contient au moins un surfactif. La matrice est essentiellement hydrophobe, mais suffisamment hydrophile pour permettre la dispersion et la dissolution du remplissage dans l'appareil gastro-intestinal.
BE9000197A 1989-02-23 1990-02-22 Compositions pharmaceutiques. BE1003123A3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898904182A GB8904182D0 (en) 1989-02-23 1989-02-23 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BE1003123A3 true BE1003123A3 (fr) 1991-12-03

Family

ID=10652220

Family Applications (1)

Application Number Title Priority Date Filing Date
BE9000197A BE1003123A3 (fr) 1989-02-23 1990-02-22 Compositions pharmaceutiques.

Country Status (26)

Country Link
US (1) US5028432A (fr)
JP (1) JP2856817B2 (fr)
KR (1) KR940006271B1 (fr)
AT (1) AT401727B (fr)
AU (1) AU629303B2 (fr)
BE (1) BE1003123A3 (fr)
CA (1) CA2010692C (fr)
CH (1) CH680567A5 (fr)
CY (1) CY1734A (fr)
DE (1) DE4005650C2 (fr)
DK (1) DK170209B1 (fr)
FR (1) FR2643263B1 (fr)
GB (2) GB8904182D0 (fr)
HK (1) HK89493A (fr)
HU (1) HU211930A9 (fr)
IE (1) IE63179B1 (fr)
IL (1) IL93490A (fr)
IT (1) IT1240768B (fr)
LU (1) LU87681A1 (fr)
NL (1) NL193267C (fr)
NZ (1) NZ232642A (fr)
PH (1) PH26972A (fr)
SA (1) SA90100287B1 (fr)
SE (1) SE512412C2 (fr)
ZA (1) ZA901348B (fr)
ZW (1) ZW1790A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004893A1 (fr) * 1990-09-13 1992-04-02 Smithkline Beecham Corporation Suspensions orales liquides non aqueuses
US5571533A (en) * 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
AU669952B2 (en) * 1992-10-16 1996-06-27 Glaxo Group Limited Taste-masking compositions of ranitidine
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
DE4341310A1 (de) * 1993-12-03 1995-06-08 Hexal Pharma Gmbh Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
GB9705813D0 (en) * 1997-03-20 1997-05-07 Smithkline Beecham Plc Novel compositions
AR013261A1 (es) * 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
ATE374602T1 (de) * 2001-12-21 2007-10-15 Supernus Pharmaceuticals Inc Orale kapselformulierung mit verbesserter physikalischer stabilität
JP2006518380A (ja) * 2003-01-31 2006-08-10 スミスクライン・ビーチャム・コーポレイション 固体分散体組成物
KR101152470B1 (ko) 2003-08-13 2012-06-01 바이오콘 리미티드 치료제용 마이크로-입자 지방산 염 고형 투약 제형
MX2012013955A (es) 2010-06-23 2013-01-24 Colgate Palmolive Co Composiciones terapeuticas bucales.
US9161891B2 (en) 2010-12-20 2015-10-20 Colgate-Palmolive Company Gelatin encapsulated oral care composition containing dental occlusion actives, hydrophobic viscosity modifier and oil carrier
CN107088168A (zh) 2010-12-20 2017-08-25 高露洁-棕榄公司 包含牙齿封闭活性物的非水性口腔护理组合物
CN103260466B (zh) 2010-12-20 2016-08-17 高露洁-棕榄公司 含有亲水性活性物质、疏水性结构化剂和油载体的明胶包囊的口腔护理组合物
US20200038376A1 (en) * 2016-11-01 2020-02-06 Johnson & Johnson Consumer Inc. Liquid oral pharmaceutical dosage form comprising an histamine h2-receptor antagonist and an antacid
CN109010303B (zh) * 2017-06-09 2021-05-07 苏州科伦药物研究有限公司 一种盐酸雷尼替丁胶囊的工业制备方法
KR102108153B1 (ko) * 2017-07-05 2020-05-07 (주)동구바이오제약 생체 이용률 및 안정성이 개선된 레티노이드를 함유하는 약제학적 조성물
KR102928295B1 (ko) * 2018-09-07 2026-02-13 알.피.쉐러 테크놀러지즈 엘엘씨 경화 및 낮은 hlb 계면 활성제(들)의 첨가를 통한 고체 또는 반고체 지질 기반 제형 안정화

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000516A1 (fr) * 1983-08-01 1985-02-14 R. P. Scherer Corporation Procede de liberation entretenue et produit relatif
GB2218333A (en) * 1988-05-11 1989-11-15 Glaxo Group Ltd Ranitidine adsorbates
GB2228198A (en) * 1989-02-20 1990-08-22 Sandoz Ltd Orally administrable cyclosporin solutions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
DE2360796B2 (de) * 1973-12-06 1977-06-02 Edelfettwerke Werner Schlüter, 2000 Hamburg; Glyco Iberica S.A., Gava, Barcelona (Spanien) Vti: Hegel, K.Th., Dr.; Dickel, K., Dipl.-Ing.; Pat.-Anwälte, 2000 Hamburg und 8000 München Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
IT1090703B (it) * 1976-12-03 1985-06-26 Scherer Ltd R P Perfezionamento nelle composizioni utili quali veicolo per farmaci
JPS5919524B2 (ja) * 1976-12-17 1984-05-07 中外製薬株式会社 安定な１α−ヒドロキシビタミンＤ類含有製剤
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
JPS55136219A (en) * 1979-04-11 1980-10-23 Sumitomo Chem Co Ltd Diazepam oily drug
EP0040489A1 (fr) * 1980-05-17 1981-11-25 FISONS plc Mélanges, sels, emballages et compositions pharmaceutiques contenant l'acide 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyrane-2-carboxylique ou un de ses dérivés et une antihistamine antagoniste des récepteurs H2
GB2084580B (en) * 1980-10-01 1984-07-04 Glaxo Group Ltd Aminoalkyl furan derivative
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
DE3264782D1 (en) * 1981-10-16 1985-08-22 Sanol Arznei Schwarz Gmbh Medicinal formulation
JPS58174308A (ja) * 1982-04-06 1983-10-13 Fujimoto Seiyaku Kk レクタルカプセル坐剤
CA1211374A (fr) * 1982-05-14 1986-09-16 Eszter Cholnoky Compose pharmaceutique contenant plus d'ingredients actifs
DE3237814A1 (de) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. Wasserfreie emulsionen und verwendung derselben
GB8426738D0 (en) * 1984-10-23 1984-11-28 Scras Pyridine derivatives
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
JPH07549B2 (ja) * 1986-07-03 1995-01-11 ゼリア新薬工業株式会社 軟カプセル充填用組成物
DE3629386A1 (de) * 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
JPH0482832A (ja) * 1988-09-20 1992-03-16 Glaxo Group Ltd 医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000516A1 (fr) * 1983-08-01 1985-02-14 R. P. Scherer Corporation Procede de liberation entretenue et produit relatif
GB2218333A (en) * 1988-05-11 1989-11-15 Glaxo Group Ltd Ranitidine adsorbates
GB2228198A (en) * 1989-02-20 1990-08-22 Sandoz Ltd Orally administrable cyclosporin solutions

Also Published As

Publication number Publication date
US5028432A (en) 1991-07-02
SA90100287B1 (ar) 1999-08-15
IL93490A (en) 1994-07-31
CA2010692A1 (fr) 1990-08-23
JP2856817B2 (ja) 1999-02-10
IT9047659A0 (it) 1990-02-22
IE63179B1 (en) 1995-03-22
HU211930A9 (en) 1996-01-29
FR2643263B1 (fr) 1994-09-16
NL9000428A (nl) 1990-09-17
ZW1790A1 (en) 1991-10-16
GB9004016D0 (en) 1990-04-18
IE900651L (en) 1990-08-23
HK89493A (en) 1993-09-03
KR940006271B1 (ko) 1994-07-14
PH26972A (en) 1992-12-28
DK48090A (da) 1990-08-24
DE4005650A1 (de) 1990-09-06
NZ232642A (en) 1992-07-28
SE9000625D0 (sv) 1990-02-22
LU87681A1 (fr) 1991-10-08
CA2010692C (fr) 1995-12-12
GB2229094A (en) 1990-09-19
DE4005650C2 (de) 1999-03-25
SE512412C2 (sv) 2000-03-13
GB8904182D0 (en) 1989-04-05
IT1240768B (it) 1993-12-17
ATA42190A (de) 1996-04-15
GB2229094B (en) 1993-01-06
IL93490A0 (en) 1990-11-29
NL193267C (nl) 1999-05-06
IT9047659A1 (it) 1991-08-22
JPH03200728A (ja) 1991-09-02
SE9000625L (sv) 1990-08-24
DK170209B1 (da) 1995-06-19
AU629303B2 (en) 1992-10-01
ZA901348B (en) 1991-03-27
CY1734A (en) 1994-05-06
DK48090D0 (da) 1990-02-22
NL193267B (nl) 1999-01-04
KR900012612A (ko) 1990-09-01
AU5007390A (en) 1990-08-30
CH680567A5 (fr) 1992-09-30
FR2643263A1 (fr) 1990-08-24
AT401727B (de) 1996-11-25

Similar Documents

Publication Publication Date Title
CA2207218C (fr) Composition a liberation regulee formant une structure micellaire inversee (l2) et une structure micellaire normale (l1)
FR2643263A1 (fr) Composition pharmaceutique a base de ranitidine
EP0277459B1 (fr) Médicament à libération controlée
US6692771B2 (en) Emulsions as solid dosage forms for oral administration
KR100535319B1 (ko) 약물방출속도가제어된의약조성물
FR2417982A1 (fr) Produit pharmaceutique solide contenant un sel de bismuth, administrable par voie orale, presentant un taux d'activite accru et un taux de solubilite constant et predetermine
DD300405A5 (de) Pharmazeutische rezepturen
KR20010032943A (ko) 오메가-3 지방산 오일을 함유하는 약학 조성물
US4339463A (en) Enterosoluble hard-capsulated medicaments
CZ51995A3 (en) Substantially anhydrous pharmaceutical preparation for oral administration of active component
BE1011363A3 (fr) Capsules semi-solides autoemulsionnables matricielles a action prolongee.
KR20010013365A (fr) Compositions de sertraline solubilisee
US5189066A (en) Pharmaceutical compositions of tebufelone
CA2437762C (fr) Emulsions en formes posologiques solides pour l'administration orale
JPH07549B2 (ja) 軟カプセル充填用組成物
EP0536277A1 (fr) Suspension d'hydrochlorure d'amantadine possedant des caracteristiques de dissolution ameliorees, utilisee dans la preparation de capsules de gelatine souples
FR2635463A1 (fr) Composition pharmaceutique comportant un principe actif peu soluble dans l'eau et au moins un glyceride gelifie par au moins un polymere cellulosique
RU2150269C1 (ru) Мягкая капсула с лактобактериями для лечения дисбактериозов влагалища
JPS60218318A (ja) 軟カプセル充填用組成物
JPH0611697B2 (ja) 経口投与持続性カプセル剤
HK89296A (en) Pharmaceutical compositions of tebufelone
JP2021172663A (ja) ルビプロストンを含む軟カプセル剤及びその製造方法
JP2000302621A (ja) 歯周病治療用徐放性製剤

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *GLAXO CANADA INC.

Effective date: 20100222